Despite an expanding therapeutic armamentarium, remission rates in inflammatory bowel disease (IBD) appear to plateau at 30-50% after 1 year of treatment, leading to the concept of a therapeutic ceiling with single agents. This Viewpoint challenges the notion ... ...

请注册登录后继续浏览